To include your compound in the COVID-19 Resource Center, submit it here.

Longwood launches Immunitas with $39M and single-cell genomics platform

Immunitas is harnessing single-cell analysis to identify new immune targets for cancer

With $39M series A, Immunitas is harnessing single-cell analysis to identify new immune targets for cancer.

Immunitas Therapeutics emerged from stealth mode on Thursday with a $39 million series A round and a single-cell genomics platform to identify novel targets for mAbs that boost antitumor immunity.

Momentum is growing around use of single-cell analysis and human tissue samples, rather than animal models, to

Read the full 627 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE